Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India

Hdl Handle:
http://hdl.handle.net/10144/311644
Title:
Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
Authors:
Burza, Sakib; Sinha, Prabhat K; Mahajan, Raman; Lima, María Angeles; Mitra, Gaurab; Verma, Neena; Balsegaram, Manica; Das, Pradeep
Journal:
PLoS Neglected Tropical Diseases
Abstract:
A proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) implemented a program in Bihar, India, using intravenous liposomal amphotericin B (Ambisome) as a first-line treatment for VL. The aim of this study was to identify risk factors for VL relapse by examining the characteristics of immunocompetent patients who relapsed following this regimen.
Publisher:
Public Library of Science
Issue Date:
Jan-2014
URI:
http://hdl.handle.net/10144/311644
DOI:
10.1371/journal.pntd.0002536
PubMed ID:
24392166
Language:
en
ISSN:
1935-2735
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorBurza, Sakiben_GB
dc.contributor.authorSinha, Prabhat Ken_GB
dc.contributor.authorMahajan, Ramanen_GB
dc.contributor.authorLima, María Angelesen_GB
dc.contributor.authorMitra, Gauraben_GB
dc.contributor.authorVerma, Neenaen_GB
dc.contributor.authorBalsegaram, Manicaen_GB
dc.contributor.authorDas, Pradeepen_GB
dc.date.accessioned2014-01-20T21:25:18Z-
dc.date.available2014-01-20T21:25:18Z-
dc.date.issued2014-01-
dc.identifier.citationRisk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients Following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India. 2014, 8 (1):e2536 PLoS Negl Trop Disen_GB
dc.identifier.issn1935-2735-
dc.identifier.pmid24392166-
dc.identifier.doi10.1371/journal.pntd.0002536-
dc.identifier.urihttp://hdl.handle.net/10144/311644-
dc.description.abstractA proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) implemented a program in Bihar, India, using intravenous liposomal amphotericin B (Ambisome) as a first-line treatment for VL. The aim of this study was to identify risk factors for VL relapse by examining the characteristics of immunocompetent patients who relapsed following this regimen.en_GB
dc.language.isoenen
dc.publisherPublic Library of Scienceen_GB
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen_GB
dc.subjectKala Azar/Visceral Leishmaniasisen_GB
dc.subjectHIV/AIDSen_GB
dc.titleRisk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, Indiaen
dc.identifier.journalPLoS Neglected Tropical Diseasesen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.